Bone Mineral Density Enhancement and Safety Evaluation of a Calcium Carbonate Compound Capsule
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
The enhancement of bone mineral density function and safety of a calcium carbonate compound capsule (Ca-CC) were evaluated in vivo. Sixty female rats were administered 0.18, 0.35, or 1.05 g/kg•bw Ca-CC daily via oral gavage for 90 days. The growth and development index, femur weight, femur bone density, and bone calcium content were determined to assess the bone mineral density enhancing effect of the capsule. Compared to the control group, the group treated with 1.05 g/kg•bw Ca-CC demonstrated an increase in the bone mineral densities of the distal and central femur by 7.39% (P<0.05) and 8.29% (P<0.01), respectively, and an increase in calcium content by 29.70% (P<0.01). To assess the safety of the capsule, Kunming mice were administered 20.00 g/kg•bw of Ca-CC. Within the tested doses, no significant strain mutation, sperm abnormality, nor anatomical or histological abnormalities were observed. During the 30-day observation period, the low (0.88 g/kg•bw), medium (1.75 g/kg•bw), and high (3.50 g/kg•bw) doses of Ca-CC had no effects on various physiological indices. Thus, Ca-CC significantly enhances the bone mineral density function in rats and is safe for consumption.
